Cellular Senescence: Defining a Path Forward

Vassilis Gorgoulis; Peter D. Adams; Andrea Alimonti; Dorothy C. Bennett; Oliver Bischof; Cleo Bishop; Judith Campisi; Manuel Collado; Konstantinos Evangelou; Gerardo Ferbeyre; Jesús Gil; Eiji Hara; Valery Krizhanovsky; Diana Jurk; Andrea B. Maier; Masashi Narita; Laura Niedernhofer; João F. Passos; Paul D. Robbins; Clemens A. Schmitt; John Sedivy; Konstantinos Vougas; Thomas von Zglinicki; Daohong Zhou; Manuel Serrano; Marco Demaria

doi:10.1016/j.cell.2019.10.005

Cellular Senescence: Defining a Path Forward

Vassilis Gorgoulis, Peter D. Adams, Andrea Alimonti, Dorothy C. Bennett, Oliver Bischof, Cleo Bishop, Judith Campisi, Manuel Collado, Konstantinos Evangelou, Gerardo Ferbeyre, Jesús Gil, Eiji Hara, Valery Krizhanovsky, Diana Jurk, Andrea B. Maier, Masashi Narita, Laura Niedernhofer, João F. Passos, Paul D. Robbins, Clemens A. SchmittJohn Sedivy, Konstantinos Vougas, Thomas von Zglinicki, Daohong Zhou, Manuel Serrano, Marco Demaria

Research output: Contribution to journal › Review article › peer-review

1856 Scopus citations

Abstract

The cellular state of “senescence” has proven difficult to define, presenting an obstacle for progress in the field. This perspective provides a consensus on the cellular and molecular features of senescence from 26 field leaders.

Original language	English (US)
Pages (from-to)	813-827
Number of pages	15
Journal	Cell
Volume	179
Issue number	4
DOIs	https://doi.org/10.1016/j.cell.2019.10.005
State	Published - Oct 31 2019

Bibliographical note

Funding Information:
We would like to thank Nikolaos Kastrinakis, Panagiotis V.S. Vasileiou, Gkikas Magiorkinis, Eleni Fitsiou, and Michela Borghesan for their valuable support to this work. We apologize in advance that, for reason of space, we have omitted the citations of relevant papers and reviews. M.D. is funded by the Dutch Cancer Foundation, Netherlands (grant ID 10989). V.G. K.E. and K.V. were financially supported by the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grants agreement no. 722729 (SYNTRAIN); the Welfare Foundation for Social & Cultural Sciences (KIKPE), Greece; the KIKPE Foundation, Athens, Greece; Pentagon Biotechnology, UK; DeepMed IO, UK; grant no. 775 from the Hellenic Foundation for Research and Innovation (HFRI); and NKUA-SARG grants 70/3/9816, 70/3/12128, and 70/3/15603. M.S.: is funded by the IRB and by grants from the Spanish Ministry of Economy co-funded by the European Regional Development Fund (ERDF) (SAF2013-48256-R), the European Research Council (ERC-2014-AdG/669622), and ?laCaixa? Foundation. M.D. is a cofounder and shareholder of Cleara Biotech and holds patents related to senolytics. A.A. is a cofounder and shareholder of Oncosence. J.C. is a cofounder and shareholder of Unity Biotechnology and holds patents related to senolytics. D.Z. is a cofounder and shareholder of Unity Biotechnology and holds patents related to senolytics. J.G. owns equity in and has acted as a consultant for Unity Biotechnology; is a scientific founder of, owns equity in, and acts as a consultant for Geras Bio; and holds patents related to senolytics. T.v.Z. is a member of the advisory boards of the Mayo Clinic Robert and Arlene Kogod Center on Aging and of Nuchido.

Funding Information:
We would like to thank Nikolaos Kastrinakis, Panagiotis V.S. Vasileiou, Gkikas Magiorkinis, Eleni Fitsiou, and Michela Borghesan for their valuable support to this work. We apologize in advance that, for reason of space, we have omitted the citations of relevant papers and reviews. M.D. is funded by the Dutch Cancer Foundation , Netherlands (grant ID 10989 ). V.G., K.E., and K.V. were financially supported by the European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grants agreement no. 722729 (SYNTRAIN); the Welfare Foundation for Social & Cultural Sciences (KIKPE), Greece; the KIKPE Foundation , Athens, Greece; Pentagon Biotechnology , UK; DeepMed IO , UK; grant no. 775 from the Hellenic Foundation for Research and Innovation (HFRI) ; and NKUA-SARG grants 70/3/9816 , 70/3/12128 , and 70/3/15603 . M.S.: is funded by the IRB and by grants from the Spanish Ministry of Economy co-funded by the European Regional Development Fund (ERDF) ( SAF2013-48256-R ), the European Research Council ( ERC-2014-AdG/669622 ), and “laCaixa” Foundation.

Publisher Copyright:
© 2019 Elsevier Inc.

Publisher link

10.1016/j.cell.2019.10.005

Find It

Find It at U of M Libraries

Cite this

Gorgoulis, V., Adams, P. D., Alimonti, A., Bennett, D. C., Bischof, O., Bishop, C., Campisi, J., Collado, M., Evangelou, K., Ferbeyre, G., Gil, J., Hara, E., Krizhanovsky, V., Jurk, D., Maier, A. B., Narita, M., Niedernhofer, L., Passos, J. F., Robbins, P. D., ... Demaria, M. (2019). Cellular Senescence: Defining a Path Forward. Cell, 179(4), 813-827. https://doi.org/10.1016/j.cell.2019.10.005

Gorgoulis, V, Adams, PD, Alimonti, A, Bennett, DC, Bischof, O, Bishop, C, Campisi, J, Collado, M, Evangelou, K, Ferbeyre, G, Gil, J, Hara, E, Krizhanovsky, V, Jurk, D, Maier, AB, Narita, M, Niedernhofer, L, Passos, JF, Robbins, PD, Schmitt, CA, Sedivy, J, Vougas, K, von Zglinicki, T, Zhou, D, Serrano, M & Demaria, M 2019, 'Cellular Senescence: Defining a Path Forward', Cell, vol. 179, no. 4, pp. 813-827. https://doi.org/10.1016/j.cell.2019.10.005

@article{945d92b9e05c4394bef35670e370c8ba,

title = "Cellular Senescence: Defining a Path Forward",

abstract = "The cellular state of “senescence” has proven difficult to define, presenting an obstacle for progress in the field. This perspective provides a consensus on the cellular and molecular features of senescence from 26 field leaders.",

author = "Vassilis Gorgoulis and Adams, {Peter D.} and Andrea Alimonti and Bennett, {Dorothy C.} and Oliver Bischof and Cleo Bishop and Judith Campisi and Manuel Collado and Konstantinos Evangelou and Gerardo Ferbeyre and Jes{\'u}s Gil and Eiji Hara and Valery Krizhanovsky and Diana Jurk and Maier, {Andrea B.} and Masashi Narita and Laura Niedernhofer and Passos, {Jo{\~a}o F.} and Robbins, {Paul D.} and Schmitt, {Clemens A.} and John Sedivy and Konstantinos Vougas and {von Zglinicki}, Thomas and Daohong Zhou and Manuel Serrano and Marco Demaria",

note = "Funding Information: We would like to thank Nikolaos Kastrinakis, Panagiotis V.S. Vasileiou, Gkikas Magiorkinis, Eleni Fitsiou, and Michela Borghesan for their valuable support to this work. We apologize in advance that, for reason of space, we have omitted the citations of relevant papers and reviews. M.D. is funded by the Dutch Cancer Foundation, Netherlands (grant ID 10989). V.G. K.E. and K.V. were financially supported by the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grants agreement no. 722729 (SYNTRAIN); the Welfare Foundation for Social & Cultural Sciences (KIKPE), Greece; the KIKPE Foundation, Athens, Greece; Pentagon Biotechnology, UK; DeepMed IO, UK; grant no. 775 from the Hellenic Foundation for Research and Innovation (HFRI); and NKUA-SARG grants 70/3/9816, 70/3/12128, and 70/3/15603. M.S.: is funded by the IRB and by grants from the Spanish Ministry of Economy co-funded by the European Regional Development Fund (ERDF) (SAF2013-48256-R), the European Research Council (ERC-2014-AdG/669622), and ?laCaixa? Foundation. M.D. is a cofounder and shareholder of Cleara Biotech and holds patents related to senolytics. A.A. is a cofounder and shareholder of Oncosence. J.C. is a cofounder and shareholder of Unity Biotechnology and holds patents related to senolytics. D.Z. is a cofounder and shareholder of Unity Biotechnology and holds patents related to senolytics. J.G. owns equity in and has acted as a consultant for Unity Biotechnology; is a scientific founder of, owns equity in, and acts as a consultant for Geras Bio; and holds patents related to senolytics. T.v.Z. is a member of the advisory boards of the Mayo Clinic Robert and Arlene Kogod Center on Aging and of Nuchido. Funding Information: We would like to thank Nikolaos Kastrinakis, Panagiotis V.S. Vasileiou, Gkikas Magiorkinis, Eleni Fitsiou, and Michela Borghesan for their valuable support to this work. We apologize in advance that, for reason of space, we have omitted the citations of relevant papers and reviews. M.D. is funded by the Dutch Cancer Foundation , Netherlands (grant ID 10989 ). V.G., K.E., and K.V. were financially supported by the European Union{\textquoteright}s Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grants agreement no. 722729 (SYNTRAIN); the Welfare Foundation for Social & Cultural Sciences (KIKPE), Greece; the KIKPE Foundation , Athens, Greece; Pentagon Biotechnology , UK; DeepMed IO , UK; grant no. 775 from the Hellenic Foundation for Research and Innovation (HFRI) ; and NKUA-SARG grants 70/3/9816 , 70/3/12128 , and 70/3/15603 . M.S.: is funded by the IRB and by grants from the Spanish Ministry of Economy co-funded by the European Regional Development Fund (ERDF) ( SAF2013-48256-R ), the European Research Council ( ERC-2014-AdG/669622 ), and “laCaixa” Foundation. Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",

year = "2019",

month = oct,

day = "31",

doi = "10.1016/j.cell.2019.10.005",

language = "English (US)",

volume = "179",

pages = "813--827",

journal = "Cell",

issn = "0092-8674",

publisher = "Elsevier B.V.",

number = "4",

}

TY - JOUR

T1 - Cellular Senescence

T2 - Defining a Path Forward

AU - Gorgoulis, Vassilis

AU - Adams, Peter D.

AU - Alimonti, Andrea

AU - Bennett, Dorothy C.

AU - Bischof, Oliver

AU - Bishop, Cleo

AU - Campisi, Judith

AU - Collado, Manuel

AU - Evangelou, Konstantinos

AU - Ferbeyre, Gerardo

AU - Gil, Jesús

AU - Hara, Eiji

AU - Krizhanovsky, Valery

AU - Jurk, Diana

AU - Maier, Andrea B.

AU - Narita, Masashi

AU - Niedernhofer, Laura

AU - Passos, João F.

AU - Robbins, Paul D.

AU - Schmitt, Clemens A.

AU - Sedivy, John

AU - Vougas, Konstantinos

AU - von Zglinicki, Thomas

AU - Zhou, Daohong

AU - Serrano, Manuel

AU - Demaria, Marco

N1 - Funding Information: We would like to thank Nikolaos Kastrinakis, Panagiotis V.S. Vasileiou, Gkikas Magiorkinis, Eleni Fitsiou, and Michela Borghesan for their valuable support to this work. We apologize in advance that, for reason of space, we have omitted the citations of relevant papers and reviews. M.D. is funded by the Dutch Cancer Foundation, Netherlands (grant ID 10989). V.G. K.E. and K.V. were financially supported by the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grants agreement no. 722729 (SYNTRAIN); the Welfare Foundation for Social & Cultural Sciences (KIKPE), Greece; the KIKPE Foundation, Athens, Greece; Pentagon Biotechnology, UK; DeepMed IO, UK; grant no. 775 from the Hellenic Foundation for Research and Innovation (HFRI); and NKUA-SARG grants 70/3/9816, 70/3/12128, and 70/3/15603. M.S.: is funded by the IRB and by grants from the Spanish Ministry of Economy co-funded by the European Regional Development Fund (ERDF) (SAF2013-48256-R), the European Research Council (ERC-2014-AdG/669622), and ?laCaixa? Foundation. M.D. is a cofounder and shareholder of Cleara Biotech and holds patents related to senolytics. A.A. is a cofounder and shareholder of Oncosence. J.C. is a cofounder and shareholder of Unity Biotechnology and holds patents related to senolytics. D.Z. is a cofounder and shareholder of Unity Biotechnology and holds patents related to senolytics. J.G. owns equity in and has acted as a consultant for Unity Biotechnology; is a scientific founder of, owns equity in, and acts as a consultant for Geras Bio; and holds patents related to senolytics. T.v.Z. is a member of the advisory boards of the Mayo Clinic Robert and Arlene Kogod Center on Aging and of Nuchido. Funding Information: We would like to thank Nikolaos Kastrinakis, Panagiotis V.S. Vasileiou, Gkikas Magiorkinis, Eleni Fitsiou, and Michela Borghesan for their valuable support to this work. We apologize in advance that, for reason of space, we have omitted the citations of relevant papers and reviews. M.D. is funded by the Dutch Cancer Foundation , Netherlands (grant ID 10989 ). V.G., K.E., and K.V. were financially supported by the European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grants agreement no. 722729 (SYNTRAIN); the Welfare Foundation for Social & Cultural Sciences (KIKPE), Greece; the KIKPE Foundation , Athens, Greece; Pentagon Biotechnology , UK; DeepMed IO , UK; grant no. 775 from the Hellenic Foundation for Research and Innovation (HFRI) ; and NKUA-SARG grants 70/3/9816 , 70/3/12128 , and 70/3/15603 . M.S.: is funded by the IRB and by grants from the Spanish Ministry of Economy co-funded by the European Regional Development Fund (ERDF) ( SAF2013-48256-R ), the European Research Council ( ERC-2014-AdG/669622 ), and “laCaixa” Foundation. Publisher Copyright: © 2019 Elsevier Inc.

PY - 2019/10/31

Y1 - 2019/10/31

N2 - The cellular state of “senescence” has proven difficult to define, presenting an obstacle for progress in the field. This perspective provides a consensus on the cellular and molecular features of senescence from 26 field leaders.

AB - The cellular state of “senescence” has proven difficult to define, presenting an obstacle for progress in the field. This perspective provides a consensus on the cellular and molecular features of senescence from 26 field leaders.

UR - http://www.scopus.com/inward/record.url?scp=85074054595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074054595&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2019.10.005

DO - 10.1016/j.cell.2019.10.005

M3 - Review article

C2 - 31675495

AN - SCOPUS:85074054595

SN - 0092-8674

VL - 179

SP - 813

EP - 827

JO - Cell

JF - Cell

IS - 4

ER -

Cellular Senescence: Defining a Path Forward

Abstract

Bibliographical note

Publisher link

Find It

Other files and links

Fingerprint

Cite this